Analysts have been eager to weigh in on the Healthcare sector with new ratings on Poseida Therapeutics (PSTX – Research Report), Sensei Biotherapeutics (SNSE – Research Report) and TScan Therapeutics (TCRX – Research Report).
Poseida Therapeutics (PSTX)
H.C. Wainwright analyst Arthur He CFA maintained a Buy rating on Poseida Therapeutics today and set a price target of $15.00. The company’s shares closed last Tuesday at $3.40.
According to TipRanks.com, CFA is a 1-star analyst with an average return of
Poseida Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $15.33.
See the top stocks recommended by analysts >>
Sensei Biotherapeutics (SNSE)
Berenberg Bank analyst Zhiqiang Shu maintained a Hold rating on Sensei Biotherapeutics today and set a price target of $6.00. The company’s shares closed last Tuesday at $1.54.
According to TipRanks.com, Shu has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Sensei Biotherapeutics is a Hold with an average price target of $6.00.
TScan Therapeutics (TCRX)
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on TScan Therapeutics, with a price target of $15.00. The company’s shares closed last Tuesday at $3.40.
According to TipRanks.com, Fein is a 3-star analyst with an average return of
TScan Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $11.67.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PSTX:
